Global Fermenters and Bioreactors Market- Distribution by Type of Product (Bioreactors and Fermenters), Fabrication Material (Glass, Stainless Steel and Single-use), Type of Bioprocess (Batch, Fed-batch and Continuous), Type of Biologic (Antibodies, Vaccines, Cell Therapies and Other Biologics), and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America): Industry Trends and Global Forecasts, 2023-2035
The global fermenters and bioreactors market is expected to reach USD 20.4 billion in 2023 anticipated to grow at a CAGR of 11.3% during the forecast period 2023-2035.
Since their inception in 1982, biologics have gained substantial favor due to their impressive therapeutic efficacy, favorable safety profiles, and their ability to address a diverse array of challenging medical conditions. Over the past two decades, the FDA has sanctioned the use of more than 170 biopharmaceuticals, with over 7,500 biological interventions currently undergoing scrutiny in clinical trials. Recognized widely is the necessity for highly specialized bioprocessing equipment in the production of these intricate biomolecules, whether at commercial or clinical scales. This equipment is indispensable for maintaining precise control over crucial bioprocess parameters, including temperature, pH levels, dissolved oxygen, fluid delivery, and other vital conditions necessary for consistent cell growth. Among this specialized equipment, bioreactors hold a pivotal role in upstream manufacturing processes by engineering optimal conditions that foster cell growth, facilitating the production of significant quantities of recombinant proteins. These proteins encompass a broad spectrum of therapeutic agents, such as vaccines, fusion proteins, antibodies, and enzymes. Notably, bioreactors also possess the capacity to produce Advanced Therapy Medicinal Products (ATMPs) like cell and gene therapies, retroviral vectors for gene therapy, and the cellular components integral to three-dimensional tissue constructs.
In contrast, fermenters find utility in the anaerobic cultivation of microbial cell populations, especially fungal or bacterial cells, to produce biologics that do not require significant post-translational modifications. It is noteworthy that employing fermenters for biologics manufacturing offers advantages including accelerated development timelines, improved yields and quality, minimized batch-to-batch variations, greater scalability, and reduced production costs when compared to manufacturing processes conducted in bioreactors.
Report Coverage
Since their inception in 1982, biologics have gained substantial favor due to their impressive therapeutic efficacy, favorable safety profiles, and their ability to address a diverse array of challenging medical conditions. Over the past two decades, the FDA has sanctioned the use of more than 170 biopharmaceuticals, with over 7,500 biological interventions currently undergoing scrutiny in clinical trials. Recognized widely is the necessity for highly specialized bioprocessing equipment in the production of these intricate biomolecules, whether at commercial or clinical scales. This equipment is indispensable for maintaining precise control over crucial bioprocess parameters, including temperature, pH levels, dissolved oxygen, fluid delivery, and other vital conditions necessary for consistent cell growth. Among this specialized equipment, bioreactors hold a pivotal role in upstream manufacturing processes by engineering optimal conditions that foster cell growth, facilitating the production of significant quantities of recombinant proteins. These proteins encompass a broad spectrum of therapeutic agents, such as vaccines, fusion proteins, antibodies, and enzymes. Notably, bioreactors also possess the capacity to produce Advanced Therapy Medicinal Products (ATMPs) like cell and gene therapies, retroviral vectors for gene therapy, and the cellular components integral to three-dimensional tissue constructs.
In contrast, fermenters find utility in the anaerobic cultivation of microbial cell populations, especially fungal or bacterial cells, to produce biologics that do not require significant post-translational modifications. It is noteworthy that employing fermenters for biologics manufacturing offers advantages including accelerated development timelines, improved yields and quality, minimized batch-to-batch variations, greater scalability, and reduced production costs when compared to manufacturing processes conducted in bioreactors.
Report Coverage
- The analysis investigates the fermenters and bioreactors market, examining product types, fabrication materials, bioprocess variations, biologic types, and major geographical regions.
- An evaluation is conducted on market growth factors (such as drivers, restraints, opportunities, and challenges) impacting the industry.
- It assesses the potential advantages and hurdles within the market, providing insights into the competitive landscape for key industry players.
- Revenue forecasts for market segments are provided concerning five significant regions.
- A comprehensive executive summary encapsulates research insights, delineating the current state and future trajectory of the global fermenters and bioreactors market over the medium to long term. The section starts with a fundamental overview of bioreactors and fermenters, encompassing their constituent elements.
- Subsequently, a detailed analysis scrutinizes the market landscape of companies involved in bioreactor and fermenter manufacturing, examining critical parameters such as establishment timelines, company size by employee count, headquarters' regional locations, global reach across North America, Europe, Asia-Pacific, and Rest of the World, product types, operational capacities spanning micro-mini to large-scale, operational scales (preclinical, clinical, and commercial), scalability, bioprocess methodologies (batch, fed-batch, and continuous), cell culture types (2D, 3D, and 4D), operational modes (manual, semi-automatic, and automatic), and end-user categories (academic institutes, research laboratories, biopharmaceutical and pharmaceutical industries, contract manufacturing organizations, and contract research organizations).
- A comprehensive assessment of the competitive landscape in fermenter and bioreactor manufacturing is presented. This evaluation focuses on manufacturers' strengths in terms of experience, company size, robust portfolio encompassing geographical outreach, product types, portfolio size, bioreactor/fermenter types, capacities, operational scales, scalability, bioprocess methods, cell culture types, operational modes, and end-user targets.
- In-depth profiles of pivotal fermenter and bioreactor manufacturers, selected based on cumulative strengths and product portfolios, are outlined. Each profile includes a concise company overview, pertinent financial information (where available), product portfolios, recent developments, and an insightful future outlook.
- The global installed capacity of bioreactors and fermenters, dedicated to biologics production, is estimated using publicly available data. This estimation details the distribution of capacity across fabrication materials (glass, stainless steel, single-use), cell culture sources (mammalian, microbial, others), reactor volumes, manufacturer types (in-house, hybrid, CMOs), and key geographical regions (North America, Europe, Asia-Pacific, Rest of the World).
- A detailed case study scrutinizes the market landscape of bioprocess controllers and automation systems, elucidating their scale of operation (laboratory, clinical, commercial), prominent features (scalability, user-friendliness, visual data display, remote accessibility, system control sensors, I/O compatibility, alarm/alert provisions), compatibility with various bioreactor systems, supported bioprocess types, and controlled process types. Furthermore, it provides insights into companies developing bioprocess control software, upstream and downstream controllers, including establishment timelines, company sizes, and headquarters' locations.
- Applikon Biotechnology
- Bionet
- Cytiva
- Eppendorf
- Merck
- Ollital Technology
- Parr Instrument Company
- Sartorius
- Shanghai Bailun Biological Technology
- Solaris Biotech
- Solida Biotech
- Zhengzhou Laboao Instrument Equipment (LABAO)
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Bioreactors
3.3. Components of a Bioreactor
3.4. Types of Bioreactors
3.4.1. Classification based on Type of Bioprocess
3.4.2. Classification based on Mode of Action
3.5. Applications of Bioreactors
3.6. Future Perspectives
4. FERMENTER AND BIOREACTOR MANUFACTURERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Fermenter and Bioreactor Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region of Headquarters
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Year of Establishment and Region of Headquarters
4.2.6. Analysis by Company Size and Region of Headquarters
4.2.7. Analysis by Year of Establishment, Company Size and Region of Headquarters
4.2.8. Analysis by Geographical Reach
4.2.9. Analysis by Region of Headquarters and Geographical Reach
4.2.10. Analysis by Type of Product
4.2.11. Analysis by Capacity
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Scalability
4.2.14. Analysis by Type of Bioprocess
4.2.15. Analysis by Type of Cell Culture
4.2.16. Analysis by Mode of Operation
4.2.17. Analysis by Type of End-user
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Small Companies
5.4.1. Company Competitiveness Analysis: Small Companies based in North America
5.4.2. Company Competitiveness Analysis: Small Companies based in Europe
5.4.3. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: Mid-sized Companies
5.5.1. Company Competitiveness Analysis: Mid-sized Companies based in North America
5.5.2. Company Competitiveness Analysis: Mid-sized Companies based in Europe
5.5.3. Company Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
5.6. Company Competitiveness Analysis: Large and Very Large Companies
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Applikon Biotechnology (acquired by Getinge)
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Bionet
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Cytiva
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Eppendorf
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Merck
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Ollital Technology
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Parr Instrument Company
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Sartorius
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Product Portfolio
6.9.4. Recent Developments and Future Outlook
6.10. Shanghai Bailun Biological Technology
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Solaris Biotech (acquired by Donaldson Company)
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Solida Biotech
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
6.13. Zhengzhou Laboao Instrument Equipment (LABAO)
6.13.1. Company Overview
6.13.2. Product Portfolio
6.13.3. Recent Developments and Future Outlook
7. CAPACITY ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.2.1 Bioreactors and Fermenters: Global Installed Capacity of Biologics
7.2.1.1. Analysis by Fabrication Material
7.2.1.2. Analysis by Source of Cell Culture
7.2.1.3. Analysis by Reactor Volume
7.2.1.4. Analysis by Type of Manufacturer
7.2.1.5. Analysis by Key Geographical Regions
7.3. Concluding Remarks
8. CASE STUDY: BIOPROCESS CONTROLLERS AND AUTOMATION SYSTEMS
8.1. Chapter Overview
8.2. Bioprocess Control Software: Overall Market Landscape
8.2.1. Analysis by Scale of Operation
8.2.2. Analysis by Key Features
8.2.3. Analysis by Compatibility with System
8.2.4. Analysis by Type of Process Controlled
8.3. Bioprocess Control Software Developers: Overall Market Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.4. Upstream Controllers: Overall Market Landscape
8.4.1. Analysis by Scale of Operation
8.4.2. Analysis by Key Features
8.4.3. Analysis by Compatibility with Bioreactor System
8.4.4. Analysis by Type of Bioprocess
8.4.5. Analysis by Type of Process Controlled
8.5. Upstream Controller Developers: Overall Market Landscape
8.5.1. Analysis by Year of Establishment
8.5.2. Analysis by Company Size
8.5.3. Analysis by Location of Headquarters
8.6. Downstream Controller Systems: Overall Market Landscape
8.6.1. Analysis by Scale of Operation
8.6.2. Analysis by Key Features
8.6.3. Analysis by Type of System
8.6.4. Analysis by Type of Bioprocess
8.6.5. Analysis by Application Area
8.7. Downstream Controller System Developers: Overall Market Landscape
8.7.1. Analysis by Year of Establishment
8.7.2. Analysis by Company Size
8.7.3. Analysis by Location of Headquarters
9. MARKET FORECAST
9.1. Chapter Overview
9.2. Key Assumptions and Forecast Methodology
9.3. Global Fermenters and Bioreactors Market, 2023-2035
9.3.1. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Product
9.3.1.1. Global Bioreactors Market, 2023-2035
9.3.1.2. Global Fermenters Market, 2023-2035
9.3.2. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Fabrication Material
9.3.2.1. Global Glass Fermenters and Bioreactors Market, 2023-2035
9.3.2.2. Global Stainless Steel Fermenters and Bioreactors Market, 2023-2035
9.3.2.3. Global Single Use Fermenters and Bioreactors Market, 2023-2035
9.3.3. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
9.3.3.1. Global Fermenters and Bioreactors Market for Batch and Fed-batch Process, 2023-2035
9.3.3.2. Global Fermenters and Bioreactors Market for Continuous Process, 2023-2035
9.3.4. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Biologic
9.3.4.1. Global Fermenters and Bioreactors Market for Antibodies, 2023-2035
9.3.4.2. Global Fermenters and Bioreactors Market for Vaccines, 2023-2035
9.3.4.3. Global Fermenters and Bioreactors Market for Cell Therapies, 2023-2035
9.3.4.4. Global Fermenters and Bioreactors Market for Other Biologics, 2023-2035
9.3.5. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
9.3.5.1. Global Fermenters and Bioreactors Market in North America, 2023-2035
9.3.5.2. Global Fermenters and Bioreactors Market in Europe, 2023-2035
9.3.5.3. Global Fermenters and Bioreactors Market in Asia-Pacific, 2023-2035
9.3.5.4. Global Fermenters and Bioreactors Market in Middle East and North Africa, 2023-2035
9.3.5.5. Global Fermenters and Bioreactors Market in Latin America, 2023-2035
10. EXECUTIVE INSIGHTS
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Bioreactors
3.3. Components of a Bioreactor
3.4. Types of Bioreactors
3.4.1. Classification based on Type of Bioprocess
3.4.2. Classification based on Mode of Action
3.5. Applications of Bioreactors
3.6. Future Perspectives
4. FERMENTER AND BIOREACTOR MANUFACTURERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Fermenter and Bioreactor Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region of Headquarters
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Year of Establishment and Region of Headquarters
4.2.6. Analysis by Company Size and Region of Headquarters
4.2.7. Analysis by Year of Establishment, Company Size and Region of Headquarters
4.2.8. Analysis by Geographical Reach
4.2.9. Analysis by Region of Headquarters and Geographical Reach
4.2.10. Analysis by Type of Product
4.2.11. Analysis by Capacity
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Scalability
4.2.14. Analysis by Type of Bioprocess
4.2.15. Analysis by Type of Cell Culture
4.2.16. Analysis by Mode of Operation
4.2.17. Analysis by Type of End-user
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Small Companies
5.4.1. Company Competitiveness Analysis: Small Companies based in North America
5.4.2. Company Competitiveness Analysis: Small Companies based in Europe
5.4.3. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: Mid-sized Companies
5.5.1. Company Competitiveness Analysis: Mid-sized Companies based in North America
5.5.2. Company Competitiveness Analysis: Mid-sized Companies based in Europe
5.5.3. Company Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
5.6. Company Competitiveness Analysis: Large and Very Large Companies
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Applikon Biotechnology (acquired by Getinge)
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Bionet
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Cytiva
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Eppendorf
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Merck
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Ollital Technology
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Parr Instrument Company
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Sartorius
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Product Portfolio
6.9.4. Recent Developments and Future Outlook
6.10. Shanghai Bailun Biological Technology
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Solaris Biotech (acquired by Donaldson Company)
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Solida Biotech
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
6.13. Zhengzhou Laboao Instrument Equipment (LABAO)
6.13.1. Company Overview
6.13.2. Product Portfolio
6.13.3. Recent Developments and Future Outlook
7. CAPACITY ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.2.1 Bioreactors and Fermenters: Global Installed Capacity of Biologics
7.2.1.1. Analysis by Fabrication Material
7.2.1.2. Analysis by Source of Cell Culture
7.2.1.3. Analysis by Reactor Volume
7.2.1.4. Analysis by Type of Manufacturer
7.2.1.5. Analysis by Key Geographical Regions
7.3. Concluding Remarks
8. CASE STUDY: BIOPROCESS CONTROLLERS AND AUTOMATION SYSTEMS
8.1. Chapter Overview
8.2. Bioprocess Control Software: Overall Market Landscape
8.2.1. Analysis by Scale of Operation
8.2.2. Analysis by Key Features
8.2.3. Analysis by Compatibility with System
8.2.4. Analysis by Type of Process Controlled
8.3. Bioprocess Control Software Developers: Overall Market Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.4. Upstream Controllers: Overall Market Landscape
8.4.1. Analysis by Scale of Operation
8.4.2. Analysis by Key Features
8.4.3. Analysis by Compatibility with Bioreactor System
8.4.4. Analysis by Type of Bioprocess
8.4.5. Analysis by Type of Process Controlled
8.5. Upstream Controller Developers: Overall Market Landscape
8.5.1. Analysis by Year of Establishment
8.5.2. Analysis by Company Size
8.5.3. Analysis by Location of Headquarters
8.6. Downstream Controller Systems: Overall Market Landscape
8.6.1. Analysis by Scale of Operation
8.6.2. Analysis by Key Features
8.6.3. Analysis by Type of System
8.6.4. Analysis by Type of Bioprocess
8.6.5. Analysis by Application Area
8.7. Downstream Controller System Developers: Overall Market Landscape
8.7.1. Analysis by Year of Establishment
8.7.2. Analysis by Company Size
8.7.3. Analysis by Location of Headquarters
9. MARKET FORECAST
9.1. Chapter Overview
9.2. Key Assumptions and Forecast Methodology
9.3. Global Fermenters and Bioreactors Market, 2023-2035
9.3.1. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Product
9.3.1.1. Global Bioreactors Market, 2023-2035
9.3.1.2. Global Fermenters Market, 2023-2035
9.3.2. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Fabrication Material
9.3.2.1. Global Glass Fermenters and Bioreactors Market, 2023-2035
9.3.2.2. Global Stainless Steel Fermenters and Bioreactors Market, 2023-2035
9.3.2.3. Global Single Use Fermenters and Bioreactors Market, 2023-2035
9.3.3. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
9.3.3.1. Global Fermenters and Bioreactors Market for Batch and Fed-batch Process, 2023-2035
9.3.3.2. Global Fermenters and Bioreactors Market for Continuous Process, 2023-2035
9.3.4. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Type of Biologic
9.3.4.1. Global Fermenters and Bioreactors Market for Antibodies, 2023-2035
9.3.4.2. Global Fermenters and Bioreactors Market for Vaccines, 2023-2035
9.3.4.3. Global Fermenters and Bioreactors Market for Cell Therapies, 2023-2035
9.3.4.4. Global Fermenters and Bioreactors Market for Other Biologics, 2023-2035
9.3.5. Global Fermenters and Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
9.3.5.1. Global Fermenters and Bioreactors Market in North America, 2023-2035
9.3.5.2. Global Fermenters and Bioreactors Market in Europe, 2023-2035
9.3.5.3. Global Fermenters and Bioreactors Market in Asia-Pacific, 2023-2035
9.3.5.4. Global Fermenters and Bioreactors Market in Middle East and North Africa, 2023-2035
9.3.5.5. Global Fermenters and Bioreactors Market in Latin America, 2023-2035
10. EXECUTIVE INSIGHTS
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
